USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license ...

Novo Nordisk (NYSE: NVO) is working with Durham-based IMMvention Therapeutix to jointly develop oral therapies for the disease and other chronic conditions. The companies did not disclose the ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co-develop oral treatments for the red blood cell disorder and other ...

Under the agreement, Novo Nordisk will gain an exclusive worldwide license to IMMvention’s BACH1 program. The companies will work together closely to advance BACH1 inhibitors from the program to ...

IMMvention partners with Novo Nordisk to co-develop oral therapies for sickle cell disease using BACH1 inhibitors. Novo Nordisk to handle further development, regulatory, and commercialization ...

DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- IMMvention Therapeutix ... a strategic collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell ...

Immvention Therapeutix is partnering with Novo Nordisk to develop oral treatments for sickle cell disease (SCD) and other ...

Immvention Therapeutix Inc. has entered into a collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease and other chronic conditions.